From Kickstarter Success and Shark Tank to Nasdaq Debut, Virtuix Pioneers Movement in AI-Generated Worlds and Is Ready to Scale Virtuix has released a new video showcasing how Gaussian splatting rapidly turns 360-degree camera footage into photorealistic 3D digital environments AUSTIN, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Virtuix Inc. (NASDAQ: VTIX), a leading developer of full-body virtual reality systems, today announced that its Class A ordinary shares will start trading today on the Global M ...

New partnerships with Lüt and GreenCard expand access to reliable, compliant payment options, strengthening flexibility, redundancy, and business continuity for operators.DENVER, Jan. 27, 2026 (GLOBE NEWSWIRE) -- SHF Holdings, Inc., d/b/a Safe Harbor (the “Company” or “Safe Harbor”) (NASDAQ: SHFS), a leading fintech platform serving the banking, lending, and financial services needs of the regulated cannabis and hemp industries, announced a strategic expansion of its payments solutions portfolio through par ...

CONROE, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- via IBN -- Olenox Industries Inc. (NASDAQ: OLOX) (“Olenox Industries” or the “Company”) is pleased to announce it has commenced the process of recommissioning its 162 miles of pipe as a wet gas pipeline. The recommissioned pipeline will be both a producer of NGLs (Natural Gas Liquids) and dry gas. NGLs are high-value products commonly used in blending lower grade crude through the midstream markets. The dry gas will be sold into the open market and open contr ...

MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held January 28 through February 1, 2026, in Dublin, Ireland. The presentations highlight clinical data in pulmonary arterial hypertension (PAH) and pulmonary hypertension as ...

Sale of a legacy Mark IV-g satellite enables HEO to expand its specialised Non-Earth Imaging services while providing a dedicated on-orbit testbed that grants Australian interests priority access for remote sensing developmentSYDNEY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Satellogic, Inc. (NASDAQ: SATL) and HEO today announced a landmark agreement that establishes a significant new pillar of Australian sovereign space capability. Through the full title acquisition of the in-orbit NewSat-34™ satellite, a legacy M ...

CHICAGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Portillo's, the iconic Chicago-based fast-casual restaurant famous for its Italian beef sandwiches, char-broiled burgers, crinkle-cut fries, cake shakes and more, is heating up Valentine’s Day with the launch of five new flavor-packed dipping sauces available at all restaurants nationwide starting today. To celebrate the launch, Portillo’s is offering members of its loyalty program, Portillo’s Perks, an exclusive opportunity to dip, dunk and discover its bolder fl ...

Core Viewpoint - Quoin Pharmaceuticals has received confirmation from the Japanese MHLW that its lead product candidate QRX003 qualifies for both Orphan Drug Designation and Fast Track regulatory review in Japan, aiming to self-commercialize the product if approved [1][3]. Group 1: Regulatory Designation - QRX003 has been granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency in 2025, and is now seeking similar status in Japan [1][2]. - The MHLW's Orphan Drug Designation program offers benefits such as R&D subsidies, tax credits for clinical testing, reduced application fees, priority review, and ten years of market exclusivity if approved [2]. Group 2: Clinical Development - QRX003 lotion (4%) is currently being evaluated in two late-stage pivotal clinical trials for Netherton Syndrome, with enrollment expected to be completed in the first half of 2026 [3]. - Top-line data from these trials is anticipated in the second half of 2026, with a New Drug Application (NDA) submission planned for late 2026 or early 2027 [3]. Group 3: Company Strategy - The company plans to establish its own commercial infrastructure in Japan, which is one of the three core territories for QRX003 and other pipeline products [3]. - Quoin Pharmaceuticals is committed to completing the clinical development of QRX003 urgently to address the needs of patients suffering from Netherton Syndrome [3].

NORTH PALM BEACH, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced allocating further capital to its digital treasury management strategy with the purchase of Bitcoin, bringing its total allocation in cryptocurrency to $18 million across Bitcoin and Ethereum. The investment has been executed according to internally developed models to preserve long-term optionality across volatile market regimes and was made as part of the Company’s bro ...

Atlanta, GA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- ScanTech AI Systems Inc. (the "Company" or "ScanTech AI") (Nasdaq: STAI) today announced that its Chief Executive Officer, Dolan Falconer, and Chief Financial Officer, James White, presented on behalf of the Company at a hearing before the Nasdaq Hearings Panel on January 22, 2026. During the hearing, management outlined the Company’s progress to date and its ongoing plan to address the remaining listing compliance matter, consistent with the written submission ...

VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that a compassionate benefactor has formally committed funding to support the Company’s Expanded Access Pro ...